Saturday 17 October 2026
Export BDRX’s income statement to Excel — free account
Biodexa Pharmaceuticals PLC Unsponsored ADR
BDRX Healthcare Biotechnology
Biodexa Pharmaceuticals PLC Unsponsored ADR’s revenue for fiscal 2023 (year ended December 2023) was $473,900.00, down 45.2% from fiscal 2022.
0.46
0.03
+6.98%
Follow BDRX
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
1.75 | 3.63 | 2.03 | 2.41 | |
Current Ratio |
1.75 | 3.63 | 2.03 | 2.41 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
4.92% | 3.38% | 0.34% | 0.00% | |
Debt/Equity |
0.09 | 0.04 | 0.01 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.04) | (2.67) | 0.08 | (9.12) | |
Intangible Assets out of Total Assets |
0.38 | 0.38 | 0.31 | 0.47 | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(15.68) | (4.91) | (7.35) | (7.15) | |
Working Capital |
4.83 | 8.70 | 8.33 | 5.25 | |
Capital Expenditures |
(0.01) | (0.50) | 0.02 | (0.97) | |
Net Current Asset Value |
3.01 | 7.48 | 7.48 | 4.81 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.71 | 4.59 | 3.24 | 3.88 | |
Average Payables |
3.13 | 2.04 | 2.48 | 2.16 | |
Average Assets |
12.86 | 14.88 | 18.54 | 17.35 | |
Average Common Equity |
7.27 | 10.95 | 10.43 | 11.96 |
Columns are period end dates